FSTL1 promotes cancer cell invasion through pro-invasive and pro-inflammatory pathways
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo sapiens
PROVIDER: GSE63329 | GEO | 2017/08/09
SECONDARY ACCESSION(S): PRJNA267522
REPOSITORIES: GEO
Similar Datasets
Project description:This study identifies FSTL1 as key component of intiating keratinocyte migration in skin Total RNA from N/TERT-1 keratinocytes transfected with a non-targeting siRNA or Smartpool siRNA against FSTL1 were subjected to microarray analysis
2013-03-02 | E-GEOD-41615 | biostudies-arrayexpress
Project description:This study identifies FSTL1 as key component of intiating keratinocyte migration in skin
2013-03-02 | GSE41615 | GEO
Project description:Clear cell renal cell carcinoma (ccRCC), the major histotype of cancer derived from kidney, is lack of robust prognostic and/or predictive biomarker and powerful therapeutic target. We previously identified that follistatin-like protein 1 (FSTL1) was significantly down-regulated in ccRCC at the transcription level. In the present study, we characterized, for the first time, that FSTL1 immunostaining was selectively positive in the cytoplasm of distal convoluted tubules. The expression of FSTL1 was significantly lower in ccRCC tissues than in adjacent renal tissues (P<0.001), as measured using immunohistochemistry in 69 patients with paired specimens, and lower in most ccRCC cell lines than in human embryonic kidney cells, as measured by quantitative RT-PCR. Multivariate Cox regression analysis in 89 patients with follow-up data showed that FSTL1 expression in tumors conferred a favorable postoperative prognosis independently, with a hazard ratio of 0.325 (95% confidence interval: 0.118-0.894). FSTL1 knockdown promoted anchorage independent growth, mobility, and invasion of ccRCC cell lines and promoted cell cycle from G0/G1 phases into S phase; while over-expression of FSTL1 significantly attenuated cell migration ability in ACHN cells. FSTL1 knockdown resulted in decreased expression of E-cadherin and increased expression of N-cadherin in ccRCC cell lines significantly, indicating that FSTL1 may attenuate epithelial to mesenchymal transition in ccRCC. Microarray assay indicated that NF-κB and HIF-2α pathways were activated following FSTL1 knockdown in ccRCC cells. Our study indicates that FSTL1 serves as a tumor suppressor in ccRCC, up-regulation of FSTL1 in cancer cells may be a candidate target therapy for advanced ccRCC. RNA samples were collected from NRCC-shsiscramble, NRCC-shFSTL1-1 and NRCC-shFSTL1-2 cells. Then samples were hybridized to Affymetrix arrays for mRNA profiling.
2016-01-20 | E-GEOD-76948 | biostudies-arrayexpress
Project description:Clear cell renal cell carcinoma (ccRCC), the major histotype of cancer derived from kidney, is lack of robust prognostic and/or predictive biomarker and powerful therapeutic target. We previously identified that follistatin-like protein 1 (FSTL1) was significantly down-regulated in ccRCC at the transcription level. In the present study, we characterized, for the first time, that FSTL1 immunostaining was selectively positive in the cytoplasm of distal convoluted tubules. The expression of FSTL1 was significantly lower in ccRCC tissues than in adjacent renal tissues (P<0.001), as measured using immunohistochemistry in 69 patients with paired specimens, and lower in most ccRCC cell lines than in human embryonic kidney cells, as measured by quantitative RT-PCR. Multivariate Cox regression analysis in 89 patients with follow-up data showed that FSTL1 expression in tumors conferred a favorable postoperative prognosis independently, with a hazard ratio of 0.325 (95% confidence interval: 0.118-0.894). FSTL1 knockdown promoted anchorage independent growth, mobility, and invasion of ccRCC cell lines and promoted cell cycle from G0/G1 phases into S phase; while over-expression of FSTL1 significantly attenuated cell migration ability in ACHN cells. FSTL1 knockdown resulted in decreased expression of E-cadherin and increased expression of N-cadherin in ccRCC cell lines significantly, indicating that FSTL1 may attenuate epithelial to mesenchymal transition in ccRCC. Microarray assay indicated that NF-κB and HIF-2α pathways were activated following FSTL1 knockdown in ccRCC cells. Our study indicates that FSTL1 serves as a tumor suppressor in ccRCC, up-regulation of FSTL1 in cancer cells may be a candidate target therapy for advanced ccRCC.
2016-01-20 | GSE76948 | GEO
Project description:Inter-organ crosstalk has gained more and more attention recently. However, the mechanisms under this remain incompletely understood. Here, we revealed an endocrine pathway regulated by skeletal muscle IRF4 that manipulates liver pathology. We studied that skeletal muscle specifically deleted IRF4 (F4MKO) mice showed ameliorated liver steatosis, inflammation and fibrosis, without changes in body weight on NASH diet. Proteomics analysis of serum suggested that follistatin-like protein 1 (FSTL1), as a myokine, might linked the communication between skeletal muscle and liver. Dual luciferase assays showed that IRF4 can transcriptionally regulated FSTL1 and reconstitution of FSTL1 expression in skeletal muscle of F4MKO mice, using adeno-associated virus, was sufficient to restore the liver pathology. Furthermore, we performed co-culture experiments to verify different receptors contribute to FSTL1’s function in different cell types of liver. Finally, we found serum FSTL1 level was positively correlated with NASH progression in human, whereas the mRNA level of Fstl1 and its receptors were downregulated in liver biopsy from NASH patients. These data reveal a signaling pathway from skeletal muscle to liver via IRF4-FSTL1-receptors in the pathogenesis of NASH and implicate useful targets for the management of NASH.
2023-09-11 | GSE216378 | GEO
Project description:In this study Guo et al. revealed an endocrine pathway regulated by skeletal muscle IRF4 that manipulates liver pathology. Mice with skeletal muscle specific ablation of IRF4 show ameliorated liver steatosis, inflammation, and fibrosis, without changes in body weight on nonalcoholic steatohepatitis (NASH) diet. Proteomics analysis of mouse serum suggested that follistatin-like protein 1 (FSTL1) might link the communication between muscle and liver. Dual luciferase assays showed that IRF4 could transcriptionally regulate FSTL1 and reconstitution of FSTL1 expression in muscle of F4MKO mice was sufficient to restore the liver pathology. Furthermore, co-culture experiments verified that FSTL1 exerts its function in hepatocyte, macrophage, and hepatic satellite cells through CD14 and DIP2A, CD14, DIP2A, respectively. In human, serum FSTL1 is increased in NASH patients, but the mRNA level of Fstl1 and its receptors are decreased in NASH liver biopsy, suggesting the increased serum FSTL1 is from skeletal muscle as studied in F4MKO mice. These data unveiled a signaling pathway from skeletal muscle to liver via IRF4-FSTL1-DIP2A/CD14 in the pathogenesis of NASH.
2023-09-13 | PXD045324 | Pride
Project description:The matricellular protein follistatin-like 1 (FSTL1) regulates lung development and saccular formation. Here, we employed single-cell RNA sequencing (scRNA-seq) to construct a transcriptomic atlas of 22,774 individual cells in wild-type (WT) and Fstl1–/– lung (E18.5) samples and identified 27 cell subtypes. We reveal abnormal population sizes and gene expression profiles in diverse cell subtypes in Fstl1–/– lung samples. We identify Pdgfra and Tgfbi as genetic markers specifically expressed in postnatal myofibroblasts (MyoFBs). Fstl1 deletion decreases the number of MyoFB cells and downregulates their roles in ECM organization and muscle tissue/vasculature development, in part, through the TGF-β1/BMP4 signaling pathway. Our data provide a single-cell view of the cellular heterogeneity and the molecular mechanisms underlying abnormal saccular formation and atelectatic lungs in Fstl1–/– mice.
2023-11-03 | GSE225463 | GEO
Project description:Aim to investigate the role of FSTL1 in brown adipose tissue (BAT) development and function
2021-12-31 | GSE148888 | GEO
Project description:We demonstrate that FSTL1 down-regulation shRNAs significantly increased cell migration and invasion in lung cancer cell lines in vitro, as well as in lung metastases in vivo We used microarrays to analyze the FSTL1 regulated gene expression underlying invasion-metastasis cascade.
2021-03-31 | GSE79682 | GEO
Project description:Syndecans are cell surface proteoglycans that are involved in many physiopathological processes. To unveil the known signaling effects of shed Syndecan-1 (SDC1) in oral squamous cell carcinoma (OSCC), we overexpressed SDC1 ectodomain and its bioactive peptide and performed immunoaffinity purification followed by mass spectrometry analysis. Follistatin-related protein 1 (FSTL1) was identified with both overexpressed SDC1 forms, and their interaction was confirmed by the solid-phase binding, dot-blotting, confocal co-immunolocalization and selected reaction monitoring (SRM). We have also identified Activin A (ActA) in the SDC1 and pepSDC1 complexes. To further investigate the cross talk between these proteins, singled or doubled silenced SDC1 and FSTL1 OSCC cells were evaluated in an orthotopic mouse model. Tumor tissues showed an opposite epithelial-mesenchymal transition factors regulation, in which singled shSDC1 tissue showed decreased, while singled shFSTL1 and doubled shSDC1-FSTL1 tissues showed increased mRNA levels compared with the control. By Ki-67 immunoreactivity, shFSTL1 showed a higher proliferation than control, which can be explained by the increase in ActA and its receptors mRNA levels. These findings indicate that SDC1 and FSTL1 coordinate individually these two signaling events, acting more strongly on cell invasion and proliferation, respectively. To translate these effects on patient outcome based on their mRNA expression levels, we demonstrated that patients who have individual expression of SDC1 showed higher experience of metastasis than SDC1 and FSTL1 co-expression. This study underscores for the first time the close relationship between SDC1 and FSTL1, signaling, improving our understanding of the role of syndecan-1 in cancer progression.
2022-02-28 | PXD008377 | Pride